Swiss pharmaceutical firm Actelion Ltd. (ALIOF.PK) reported a plunge in its first-quarter GAAP net income to 45.06 million Swiss francs or 0.38 Swiss francs per share from the prior year's 146.29 million Swiss francs or 1.20 Swiss francs per share. Core earnings per share declined 31% to 0.66 Swiss francs during the latest quarter.
Total net revenue slipped to 417.47 million Swiss francs from 528.23 million Swiss francs a year earlier.
Product sales for the quarter reached 415.8 million Swiss francs, compared with 450.1 million Swiss francs last year, down by 4% in local currencies. In addition, the company reaffirmed its 2012 flat core earnings forecast.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.